HIV gp120 DNA vaccine - Chiron/PowderJect

Drug Profile

HIV gp120 DNA vaccine - Chiron/PowderJect

Latest Information Update: 22 Dec 2000

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chiron Corporation; PowderJect Vaccines
  • Class AIDS vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 22 Dec 2000 Discontinued-Preclinical for HIV-1 infections in USA (IM)
  • 12 Aug 1997 Preclinical development for HIV-1 infections in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top